CYP17- and CYP11B-dependent steroid hydroxylases as drug development targets

Pharmacology and Therapeutics

Volumn 111, Issue 1, 2006, Pages 27-52

  Hakki, Tarek ^a   Bernhardt, Rita ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

CYP11B1; CYP11B2; CYP17; Heart fibrosis; Hypertension; Prostate cancer

Indexed keywords

ALDOSTERONE; ALDOSTERONE SYNTHASE; CYTOCHROME P450 17; ENZYME INHIBITOR; HYDROCORTISONE; KETOCONAZOLE; STEROID HORMONE; STEROID MONOOXYGENASE;

CATALYSIS; CELL CULTURE; CONGENITAL ADRENAL HYPERPLASIA; DRUG INHIBITION; DRUG MECHANISM; DRUG SYNTHESIS; ENZYME INHIBITION; HEART MUSCLE FIBROSIS; HORMONE SYNTHESIS; HUMAN; HYPERTENSION; IC 50; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSEUDOHERMAPHRODITISM; REVIEW; STEROIDOGENESIS;

ALDOSTERONE SYNTHASE; ANIMALS; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; STEROID 11-BETA-HYDROXYLASE; STEROID 17-ALPHA-HYDROXYLASE;

EID: 33646812233     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2005.07.006     Document Type: Review

References (160)

1. Akiyoshi-Shibata M., Sakaki T., Ohyama Y., Noshiro M., Okuda K., and Yabusaki Y. Further oxidation of hydroxycalcidiol by calcidiol 24-hydroxylase. A study with the mature enzyme expressed in Escherichia coli. Eur J Biochem 224 (1994) 335-343
2. Angelastro M.R., Laughlin M.E., Schatzman G.L., Bey P., and Blohm T.R. 17-(Cyclopropylamino)-androst-5-en-3-ol, a selective mechanism-based inhibitor of cytochrome P45017R (steroid 17R-hydroxylase/C17,20Lyase). Biochem Biophys Res Commun 162 (1989) 1571-1577
3. Auchus R.J. The use of computational chemistry in the study of sex steroid biosynthesis. Endocr Res 24 (1998) 541-547
4. Auchus R.J., and Miller W.L. Molecular modeling of human P450c17(17α-hydroxylase/17,20-lyase): insights into reaction mechanisms and effects of mutations. Mol Endocrinol 13 (1999) 1169-1182
5. Ayub M., and Level M. Inhibition of testicular 17 α-hydroxylase and17,20-lyase but not 3-hydroxysteroid dehydrogenase-isomerase or 17-hydroxysteroid oxidoreductase by ketoconazole and other imidazole drugs. J Steroid Biochem 28 (1987) 521-531
6. Barnes H.J., Jenkins C.M., and Waterman M.R. Baculovirus expression of bovine cytochrome P450c17 in Sf9 cells and comparison with expression in yeast, mammalian cells, and E. coli. Arch Biochem Biophys 315 (1994) 489-494
7. Baron J., Taylor W.E., and Masters B.S.S. Immunochemical studies on electron chains involving cytochrome P450: the role of the iron-sulfur protein, adrenodoxin in mixed function oxidation reaction. Arch Biochem Biophys 150 (1972) 105-115
8. Barrie S.E., Potter G.A., Goddard P.M., Haynes B.P., Dowsett M., and Jarman M. Pharmacology of novel steroidal inhibitors of cytochrome P45017R (17R-hydroxylase/C17, 20 lyase. J Steroid Biochem Mol Biol 50 (1994) 267-273
9. Barrie S.E., Rowlands M.G., Foster A.B., and Jarman M. Inhibition of 17α-hydroxylase/C17, 20Lyase by bifluranol and its analogues. J Steroid Biochem 33 (1989) 1191-1195
10. Belkina N.V., Lisurek M., Ivanov A.S., and Bernhardt R. Modelling of three-dimensional structures of cytochromes P450 11B1 and 11B2. J Inorg Biochem 87 (2001) 197-207
11. Black S.D., and Coon M.J. P-450 cytochromes: structure and function. Advan Enzymol Relat Areas Mol Biol 60 (1987) 35-87
12. Boscaro M., Barzon L., Fallo F., and Sonino N. Cushing's syndrome. Lancet 357 (2001) 783-791
13. Bostwick D.G., Cooner W.H., Denis L., Jones G.W., Scardino P.W., and Murphy G.P. The association of benign prostatic hyperplasia and cancer of the prostate. Cancer 70 (1992) 291-301
14. Böttner B., and Bernhardt R. Changed ratios of glucocorticoids/mineralocorticoids caused by point mutations in the putative I-helix regions of CYP11B1 and CYP11B2. Endocr Res 4 (1996) 455-461
15. Böttner B., Denner K., and Bernhardt R. Conferring aldosterone synthesis to human CYP11B1 by replacing key amino acid residues with CYP11B2-specific ones. Eur J Biochem 252 (1998) 458-466
16. Brilla C.G. Aldosterone and myocardial fibrosis in heart failure. Herz 25 (2000) 299-306
17. Brown N.J. Aldosterone and end-organ damage. Curr Opin Nephrol Hypertens 14 (2005) 235-241
18. Brown N., Swart P., Fenhalls G., Stevens L., Kolar N.W., and Swart A.C. Baboon CYP11B1: the localization and catalytic activity in baboon adrenal tissue. Endocr Res 28 (2002) 477-484
19. Brueggemeier, R. W., Hackett, J. C., & Diaz-Cruz, E. S. (2005). Aromatase inhibitions in the treatment of breast cancer. Endocr Rev. Retrieved from http://www.edrv.endojournals.org/cgi/rapidpdf/er.2004-0015v1
20. Bülow H.E., and Bernhardt R. Analyses of the CYP11B gene family in the guinea pig suggest the existence of a primordial CYP11B gene with aldosterone synthase activity. Eur J Biochem 269 (2002) 3838-3846
21. Bülow H.E., Möbius K., Bähr V., and Bernhardt R. Molecular cloning and functional expression of the cytochrome P450 11β-hydroxylase of the guinea pig. Biochem Biophys Res Commun 221 (1996) 304-312
22. Bureik M., Hübel K., Dragan C., Scher J., Becker H., Lenz N., et al. Development of test systems for the discovery of selective human aldosterone synthase (CYP11B2) and 11β-hydroxylase (CYP11B1) inhibitors. Discovery of a new lead compound for the therapy of congestive heart failure, myocardial fibrosis and hypertension. Mol Cell Endocr 217 (2004) 249-254
23. Bureik M., Lisurek M., and Bernhardt R. The human steroid hydroxylases CYP11B1 and CYP11B2. Biol Chem 383 (2002) 1537-1551
24. Bureik M., Schiffler B., Hiraoka Y., Vogel F., and Bernhardt R. Functional expression of human mitochondrial CYP11B2 in fission yeast and identification of a new internal electron transfer protein, etp1. Biochem 41 (2002) 2311-2321
25. Burke D.F., Lanughton C.A., and Neidle S. Homology modeling of the enzyme P450 17α-hydroxylase/ 17,20-lyase-a target for prostate cancer chemotherapy-from the crystal structure of P450BM-3. Anti-cancer Drug Des 12 (1997) 113-123
26. Campo S., Stivel M., Nicolau G., Monteagudo C., and Rivarola M. Testicular function in postpubertal male pseudohermaphroditism. Clin Endocrinol 11 (1979) 481-490
27. Cheng S.C., Suzuki K., Sadee W., and Harding B.W. Effects of spirnolactone, canrenone and carenoate-K on cytochrome P450, and 11 beta- and 18-hydroxylation in bovine and human adrenal cortical mitochondria. Endocrine 99 (1976) 1097-1106
28. Chua S.C., Szabo P., Vitek A., Grzeschik K.H., John M., and White P.C. Cloning of cDNA encoding steroid 11 β-hydroxylase (P450c11). Proc Natl Acad Sci U S A 84 (1987) 7193-7197
29. Conley A.J., and Bird I.M. The role of cytochrome P450 17 alpha-hydroxylase and 3 beta-hydroxysteroid dehydrogenase in the integration of gonadal and adrenal steroidogenesis via the delta 5 and delta 4 pathways of steroidogenesis in mammals. Biol Reprod 56 (1997) 789-799
30. Cosme J., and Johnson E.F. Engineering microsomal cytochrome P450 2C5 to be a soluble, monomeric enzyme. Mutations that alter aggregation, phospholipid dependence of catalysis, and membrane binding. J Biol Chem 275 (2000) 2545-2553
31. Curnow K.M., Slutsker L., Vitek J., Cole T., Speiser P.W., New M.I., et al. Mutations in the CYP11B1 gene causing congenital adrenal hyperplasia and hypertension cluster in exons 6, 7, and 8. Proc Natl Acad Sci U S A 90 (1993) 4552-4556
32. Curnow K.M., Tusie-Luna M.T., Pascoe L., Natarajan R., Gu J.L., Nadler J.L., et al. The product of the CYP11B2 gene is required for aldosterone biosynthesis in the human adrenal cortex. Mol Endocrinol 5 (1991) 1513-1522
33. Cutler Jr. G.B., and Laue L. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. N Engl J Med 323 (1990) 1806-1813
34. De Coster R., Wouters W., and Bruynseels J. P450-dependent enzymes as targets for prostate cancer therapy. J Steroid Biochem Mol Biol 56 (1996) 133-143
35. Delyani J.A. Mineralocorticoid receptor antagonists: the evolution of utility and pharmacology. Kidney Int 57 (2000) 1408-1411
36. Denner K., and Bernhardt R. Inhibition studies of steroid conversion mediated by CYP11B1 and CYP11B2 expressed in cell cultures. In: Ishimura K., Shimada H., and Suematsu M. (Eds). Oxygen homoeostasis and its dynamics (1998), Springer, Berlin, Germany 231-236
37. Denner K., Doehmer J., and Bernhardt R. Cloning of CYP11B1 and CYP11B2 from normal human adrenal and their functional expression in COS-7 and V79 Chinese hamster cells. Endocr Res 21 (1995) 443-448
38. Denner K., Vogel R., Schmalix W., Doehmer J., and Bernhardt R. Cloning and stable expression of the human mitochondrial cytochrome P45011B1 cDNA in V79 Chinese hamster cells and their application for testing of potential inhibitors. Pharmacogenetics 5 (1995) 89-96
39. Domalik L.J., Chaplin D.D., Kirkman M.S., Wu R.C., Liu W.W., Howard T.A., et al. Different isozymes of mouse 11 β-hydroxylase produce mineralocorticoids and glucocorticoids. Mol Endocrinol 5 (1991) 1853-1861
40. Dragan C., Zearo S., Hannemann F., Bernhardt R., and Bureik M. Efficient conversion of 11-deoxycortisol to cortisol (hydrocortisone) by recombinant fission yeast. Schizosaccharomyces pombe. FEMS Yeast Res 5 (2005) 621-625
41. Ehmer P.B., Bureik M., Bernhardt R., Muller U., and Hartmann R.W. Development of a test system for inhibitors of human aldosterone synthase (CYP11B2): screening in fission yeast and evaluation of selectivity in V79 cells. J Steroid Biochem Mol Biol 81 (2002) 173-179
42. Ehmer P.B., Jose J., and Hartmann R.W. Development of a simple and rapid assay for the evaluation of inhibitors of human 17α-hydroxylase-C(17,20)-lyase (P450cl7) by coexpression of P450cl7 with NADPH-cytochrome-P450-reductase in Escherichia coli. J Steroid Biochem Mol Biol 75 (2000) 57-63
43. Engelhardt D., and Weber M.M. Therapy of Cushing's syndrome with steroid biosynthesis inhibitors. J Steroid Biochem Mol Biol 49 (1994) 261-267
44. Erdmann B., Denner K., Gerst H., Lenz D., and Bernhardt R. Human adrenal CYP11B1: localization by in situ-hybridization and functional expression in cell cultures. Endocr Res 21 (1995) 425-435
45. Erdmann B., Gerst H., Bülow H., Lenz D., Bahr V., and Bernhardt R. Zone-specific localization of cytochrome P45011B1 in human adrenal tissue by PCR-derived riboprobes. Histochem Cell Biol 104 (1995) 301-307
46. Ferrari P. Genetics of the mineralocorticoid system in primary hypertension. Curr Hypertens Rep 4 (2002) 18-24
47. Fisher A., Friel E.C., Bernhardt R., Gomez-Sanchez C., Connell J.M., Fraser R., et al. Effects of 18-hydroxylated steroids on corticosteroid production by human aldosterone synthase and 11β-hydroxylase. J Clin Endocrinol Metab 86 (2001) 4326-4329
48. Forest M.G., Lecornu M., and de Peretti E. Familial male pseudohermaphroditism due to 17-20-desmolase deficiency. In vivo endocrine studies. J Clin Endocrinol Metab 50 (1980) 826-833
49. Goebelsmann U., Zashmann M., Davajan V., Israel R., Mestman J.H., and Mishell D.R. Male pseudohermaphroditism consistent with 17-20-desmolase deficiency. Gynecol Invest 7 (1976) 138-156
50. Gotoh O. Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences. J Biol Chem 267 (1992) 83-90
51. Grigoryev D., Kato K., Njar V., Long B., Zhi-Ling Y., Wang X., et al. Cytochrome P450c17-expressing Escherichia coli as a first-step screening system for 17-hydroxylase-C17,20-lyase inhibitors. Analytika (1999) 319-330
52. Haidar S., Ehmer P.B., Barasiin S., Batzl-Hartmann C., and Hartmann R.W. Effects of novel 17α-hydroxylase/C17,20-lyase (P450 17, CYP17) inhibitors on androgen biosynthesis in vitro and in vivo. J Steroid Biochem Mol Biol 84 (2003) 555-562
53. Hampf M., Dao N.T., Hoan N.T., and Bernhardt R. Unequal crossing-over between aldosterone synthase and 11β-hydroxylase genes causes congenital adrenal hyperplasia. J Clin Endocrinol Metab 86 (2001) 4445-4452
54. Hampf M., Swart A.C., and Swart P. Sequence of the 11 beta-hydroxylase gene from the Cape baboon (Papio ursinus). Endocr Res 4 (1996) 495-499
55. Handratta V.D., Vasaitis T.S., Njar V.C., Gediya L.K., Kataria R., Chopra P., et al. Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model. J Med Chem 48 (2005) 2972-2984
56. Hartmann R.W., Ehmer P.B., Haidar S., Hector M., Jose J., Klein C.D.P., et al. Inhibition of CYP17, a new strategy of the treatment of prostate cancer. Arch Pharm Med Chem 4 (2002) 119-128
57. Hartmann R.W., Hector M., Wachall B.G., Palusczak A., Palzer M., Hunch V., et al. Synthesis and evaluation of 17-aliphatic heterocycle-substituted steroidal inhibitors of 17α-hydroxylase/C17-20-lyase (P450 17). J Med Chem 43 (2000) 4437-4445
58. Hutschenreuter T.U., Ehmer P.B., and Hartmann R.W. Synthesis of hydroxy derivatives of highly potent non-steroidal CYP 17 inhibitors as potential metabolites and evaluation of their activity by a non cellular assay using recombinant human enzyme. J Enzyme Inhib Med Chem 19 (2004) 17-32
59. Jarman M., Barrie S.E., Deadman J.J., Houghton J., and McCague R. Hydroxyperfluoroazobenzenes: novel inhibitors of enzymes of androgen biosynthesis. J Med Chem 33 (1990) 2452-2455
60. Jemal A., Thomas A., Murray T., and Thun M. Cancer statistics. CA Cancer J Clin 52 (2002) 23-47
61. Jones K.L., and Buzdar A.U.A. Review of adjuvant hormonal therapy in breast cancer. Endocr Relat Cancer 11 (2004) 391-406
62. Kawamoto T., Mitsuuchi Y., Ohnishi T., Ichikawa Y., Yokoyama Y., Sumimoto H., et al. Cloning and expression of a cDNA for human cytochrome P-450aldo as related to primary aldosteronism. Biochem Biophys Res Commun 173 (1990) 309-316
63. Kawamoto T., Mitsuuchi Y., Toda K., Miyahara K., Yokoyama Y., Nakao K., et al. Cloning of cDNA and genomic DNA for human cytochrome P-45011 β. FEBS Lett 269 (1990) 345-349
64. Kelly S.L., Lamb D.C., Cannieux M., Greetham D., Jackson C.J., Marczylo T., et al. An old activity in the cytochrome P450 superfamily (CYP51) and a new story of drugs and resistance. Biochem Soc Trans 29 (2001) 122-128
65. Lambeth J.D., Seybert D.W., Lancaster Jr. J.R., Salerno J.C., and Kamin H. Steroidogenic electron transport in adrenal cortex mitochondria. Mol Cell Biochem 45 (1982) 13-31
66. Laughton C.A., Neidle S., Zvelebil J.M., and Strenberg M.J. A molecular model for the enzyme cytochrome P450-17α, a major target for the chemotherapy of prostatic cancer. Biochem Biophys Res Commun 171 (1990) 1160-1167
67. 5. Endocrinological and mechanistic implications. Biochem J 308 (1995) 901-908
68. Lewis D.F., and Lee-Robichaud P. Molecular modeling of steroidogenic cytochromes P450 from families CYP11, CYP17, CYP19 and CYP21 based on the crystal structure. J Steroid Biochem 308 (1998) 901-908
69. Li J.S., Li Y., Son C., and Brodie A.M. Synthesis and evaluation of pregnane derivatives as inhibitors of human testicular 17α-hydroxylase. J Med Chem 39 (1996) 4335-4339
70. Lifton R.P., Dluhy R.G., Powers M., Rich G.M., Cook S., Ulick S., et al. A chimaeric 11 β-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature 355 (1992) 262-265
71. Lifton R.P., Gharavi A.G., and Geller D.S. Molecular mechanisms of human hypertension. Cell 104 (2001) 545-556
72. Lijnen P., and Petrov V. Induction of cardiac fibrosis by aldosterone. J Mol Cell Cardiac 32 (2000) 865-879
73. Lin D., Black S.M., Nagahama Y., and Miller W.L. Steroid 17α-hydroxylase and 17,20-lyase activity of P450c17: contributions of serine 106 and P450 reductase. Endocrinology 132 (1993) 2498-2506
74. Lin D., Zhang L., Chiao E., and Miller W.L. Modeling and mutagenesis of the active site of human P450c17. Mol Endocrinol 8 (1994) 392-402
75. Lisurek M., and Bernhardt R. Modulation of aldosterone and cortisol synthesis on the molecular level. Mol Cell Endocrinol 215 (2004) 149-159
76. Long B., Grigoryev D.N., Nnane I.P., Liu Y., Ling Y.Z., and Brodie A.M. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer. Cancer Res 60 (2000) 6630-6640
77. Macconnachie A.A., Kelly K.F., Mcnamara A., Loughlin S., Gates L.J., Inglis G.C., et al. Rapid diagnosis and identification of cross-over sites in patients with glucocorticoid remediable aldosteronism. J Clin Endocrinol Metab 83 (1998) 4328-4331
78. MacFadyen R.J., Barr C.S., and Struthers A.D. Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc Res 35 (1997) 30-34
79. MacKenzie S.M., Lai M., Clark C.J., Fraser R., Gomez-Sanchez C.E., Seckl J.R., et al. 11beta-hydroxylase and aldosterone synthase expression in fetal rat hippocampal neurons. Mol Endocrinol 29 (2002) 319-325
80. Madigan M.P., Gao Y.T., Deng J., Pfeiffer R.M., Chang B.L., Zheng S., et al. CYP17 polymorphisms in relation to risks of prostate cancer and benign prostatic hyperplasia: a population-based study in China. Int J Cancer 107 (2003) 271-275
81. Mantero F., and Lucarelli G. Aldosterone antagonism in hypertension and heart failure. Ann Endocrinol (Paris) 61 (2000) 52-60
82. Matsukawa N., Nonaka Y., Ying Z., Higaki J., Ogihara T., and Okamoto M. Molecular cloning and expression of cDNAs encoding rat aldosterone synthase: variants of cytochrome P-450(11β). Biochem Biophys Res Commun 169 (1990) 245-252
83. McCague R., Rowlands M.G., Barrie S.E., and Houghton J. Inhibition of enzymes of estrogen and androgen biosynthesis by ester of 4-pyridylacetic acid. J Med Chem 33 (1990) 3050-3055
84. Megges R., Müller-Frohne M., Pfeil D., and Ruckpaul K. Microbial steroid hydroxylation enzymes in glucocorticoid production. In: Ruckpaul K., and Rein H. (Eds). Molecular mechanisms of adrenal steroidogenesis and aspects of regulation and application, frontiers in biotransformation vol. 3 (1990), Akademie Verlag, Berlin, Germany 204-243
85. Migeon C.J., and Donohoue P.A. Congenital adrenal hyperplasia caused by 21-hydroxylase deficiency. Endocrinol Metab Clin N Am 20 (1991) 277-296
86. Miller W.L. Molecular biology of steroid hormone synthesis. Endocr Rev 9 (1988) 295-318
87. Miller W.L., and Tyrell J.B. The adrenal cortex. In: Felig P., Baxter J.D., Frohmann L.A., and Broadus A.E. (Eds). Endocrinology and metabolism. 3rd ed. (1995), McGraw-Hill Press, New York 642-659
88. Miller W.L., Auchus R.J., and Geller D.H. Steroids 62 (1997) 135-144
89. Min L., Takemori H., Nonaka Y., Katoh Y., Doi J., Horike N., et al. Characterization of the adrenal-specific antigen IZA (inner zone antigen) and its role in the steroidogenesis. Mol Cell Endocrinol 215 (2004) 143-148
90. Mitani F., Mukai K., Miyamoto H., Suematsu M., and Ishimura Y. The undifferentiated cell zone is a stem cell zone in adult rat adrenal cortex. Biochem Biophys Acta 1619 (2003) 317-324
91. Mitani F., Shimizu T., Ueno R., Ishimura Y., Izumi S., Komatsu N., et al. Cytochrome P-45011 beta and P-450scc in adrenal cortex: zonal distribution and intramitochondrial localization by the horseradish peroxidase-labeled antibody method. J Histochem Cytochem 30 (1982) 1066-1074
92. Mornet E., Dupont J., Vitek A., and White P.C. Characterization of two genes encoding human steroid 11 β-hydroxylase [P-450(11) β]. J Biol Chem 264 (1989) 20961-20967
93. Naganuma H., Ojima M., and Sasano N. 11 beta-Hydroxylase in mitochondrial fractions of functioning and non-functioning adrenocortical tumors. J Exp Med 155 (1988) 81-96
94. Nakagawa Y., Yamada M., Ogawa H., and Igarashi Y. Missense mutation in CYP11B1 (CGA[Arg384] GCA[Gly]) causes steroid 11beta-hydroxylase deficiency. Eur J Endocrinol 132 (1995) 286-289
95. Nakajin S., and Hall P.F. Microsomal cytochrome from neonatal pig testis. Purification and properties of a C21 steroid side-chain cleavage system (17α-hydroxylase-C17,20-lyase). J Biol Chem 256 (1981) 3871-3876
96. Nakajin S., Hall P.F., and Onoda M. Testicular microsomal cytochrome P450 for C21 steroid side-chain cleavage. Spectral and binding studies. J Biol Chem 256 (1981) 6134-6139
97. Nakajin S., Shinoda M., Haniu M., Shively J.E., and Hall P.F. C21 steroid side-chain cleavage enzyme from porcine adrenal microsomes. Purification and characterization of the 17α-hydroxylase/C17,20 lyase cytochrome P450. J Biol Chem 259 (1984) 3971-3976
98. Nakajin S., Takahashi K., and Shinoda M. Inhibitory effect and spectral changes on pig testicular cytochrome P-450 (17αhydroxylase/C17,20-lyase) by 20-hydroxy-C21-steroids. Yakugaku Zasshi 108 (1988) 1188-1195
99. Nakajin S., Takahashi K., and Shinoda M. Inhibitory effect and interaction of stanozolol with pig testicular cytochrome P-450 (17α-hydroxylase/C17,20-lyase). Chem Pharm Bull (Tokyo) 37 (1989) 1855-1858
100. 5 promotes the synthesis of delta 16-C19 steroids by homogeneous cytochrome P-450 C21 side-chain cleavage from pig testis. Biochem Biophys Res Commun 132 (1985) 708-713
101. New M.I. Genetic disorders of adrenal hormone synthesis. Horm Res 37 (1992) 22-33
102. New M.I., Oberfield S.E., Levine L.S., Dupont B., Pollack M., Gill J.R., et al. Autosomal dominant transmission and absence of HLA linkage in dexamethasone suppressible hyperaldosteronism. Lancet 1 (1980) 550-551
103. Nnane I.P., Kato K., Liu Y., Long B.J., Lu Q., Wang X., et al. Inhibition of androgen synthesis in human testicular and prostatic microsomes and in male rats by novel steroidal compounds. Endocrine 140 (1999) 2891-2897
104. Nnane P., Njar V.C., Liu Y., Lu Q., and Brodie A.M. Effects of novel 17-azolyl compounds on androgen synthesis in vitro and in vivo. J Steroid Biochem Mol Biol 71 (1999) 145-152
105. Nonaka Y., Fujii T., Kagawa N., Waterman M.R., Takemori H., and Okamoto M. Structure/function relationship of CYP11B1 associated with Dahl's salt-resistant rats-expression of rat CYP11B1 and CYP11B2 in Escherichia coli. Eur J Biochem 258 (1998) 869-878
106. Nonaka S.Y., Takemori H., Halder S.K., Sun T., Ohta M., Hatano O., et al. Frog cytochrome P-450 (11 β,aldo), a single enzyme involved in the final steps of glucocorticoid and mineralocorticoid biosynthesis. Eur J Biochem 229 (1995) 249-256
107. O'Donnell A., Judson I., Dowsett M., Raynaud F., Dearnaley D., Mason M., et al. Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer 90 (2004) 2317-2325
108. Ogishima T., Shibata H., Shimada H., Mitani F., Suzuki H., Saruta T., et al. Aldosterone synthase cytochrome P-450 expressed in the adrenals of patients with primary aldosteronism. J Biol Chem 266 (1991) 10731-10734
109. Ohlsson G., Muller J.R., and Schwartz M. Adrenogenital syndrome-molecular biology and prenatal diagnosis. Ugeskr LAEger 160 (1998) 803-807
110. Ohyama Y., and Okuda K. Isolation and characterization of a cytochrome P-450 from rat kidney mitochondria that catalyzes the 24-hydroxylation of 25-hydroxyvitamin D3. J Biol Chem 266 (1991) 8690-8695
111. 5 stimulates purified testicular microsomal cytochrome P450 (C21 side-chain cleavage). Biochem Biophys Res Commun 108 (1982) 454-460
112. Ortiz de Montellano P.R. In: Ortiz de Montellano P.R. (Ed). Cytochrome P-450: structure, mechanism and biochemistry (1986), Plenum, New York 217-271
113. Pascoe L., Curnow K.M., Slutsker L., Connell J.M., Speiser P.W., New M.I., et al. Glucocorticoid-suppressible hyperaldosteronism results from hybrid genes created by unequal crossovers between CYP11B1 and CYP11B2. Proc Natl Acad Sci U S A 89 (1992) 8327-8331
114. Pascoe L., Jeunemaitre X., Lebrethon M.C., Curnow K.M., Gomez-Sanchez C.E., Gasc J.M., et al. Glucocorticoid-suppressible hyperaldosteronism and adrenal tumours occurring in a single French pedigree. J Clin Invest 96 (1995) 2236-2246
115. Peters J., Hampf M., Peters B., and Bernhardt R. Molekularbiologie, klinik und therapie steroidbedingter hypertonien. In: Ganten D., and Ruckpaul K. (Eds). Handbuch der Molekularen Medizin: Herz-Kreislauf-Erkrankungen (1998), Springer, Berlin, Germany 413-452
116. Pikuleva I.A., Bjorkhem I., and Waterman M.R. Expression, purification, and enzymatic properties of recombinant human cytochrome P450c27 (CYP27). Arch Biochem Biophys 343 (1997) 123-130
117. Pitt B. Do diuretics and aldosterone receptor antagonists improve ventricular remodeling?. J Card Fail 8 (2002) 491-493
118. Pitt B., Williams G., Remme W., Martinez F., Lopez-Sendon J., Zannad F., et al. The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study. Cardiovasc Drugs Ther 1 (2001) 79-87
119. Pitt B., Zannad F., Remme W.J., Cody R., Castaigne A., Peerez A., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldosterone Evaluation Study Investigators. N Engl J Med 341 (1999) 709-717
120. Porter T.D. An unusual yet strongly conserved flavoprotein in bacteria and mammals. TIBS 16 (1991) 154-158
121. Potter G.A., Barrie S.E., Jarman M., and Rowlands M. Novel steroidal inhibitors of human cytochrome P45017R (17α-hydroxylase/C17-20 lyase): potential agents for the treatment of prostatic cancer. J Med Chem 38 (1996) 2463-2471
122. Rainey W.E. Adrenal zonation: clues from 11beta-hydroxylase and aldosterone synthase. Mol Cell Endocr 151 (1999) 151-160
123. Ramires F.J., Sun Y., and Weber K.T. Myocardial fibrosis associated with aldosterone or angiotensin II administration: attenuation by calcium channel blockade. J Mol Cell Cardiol 30 (1998) 475-483
124. Rowlands M.G., Barrie S.E., Chan F., Houghton J., Jarman M., McCague R., et al. Esters of 3-pyridylacetic acid that combine potent inhibition of 17α-hydroxylase/C17,20-lyase (cytochrome P45017R) with resistance to esterase hydrolysis. J Med Chem 38 (1995) 4191-4197
125. Schiffler B., Bureik M., Reinle W., Muller E.C., Hannemann F., and Bernhardt R. The adrenodoxin-like ferredoxin of Schizosaccharomyces pombe mitochondria. J Inorg Biochem 98 (2004) 1229-1237
126. Shet M.S., Fisher C.W., Arlotto M.P., Shackleton C.H., Holmans P.L., Martin-Wixtrom C.A., et al. Purification and enzymatic properties of a recombinant fusion protein expressed in Escherichia coli containing the domains of bovine P450 17A and rat NADPH-P450 reductase. Arch Biochem Biophys 311 (1994) 402-417
127. Shet M.S., Fisher C.W., and Estabrook R.W. The function of recombinant cytochrome P450s in intact Escherichia coli cells: the 17 alpha-hydroxylation of progesterone and pregnenolone by P450c17. Arch Biochem Biophys 339 (1997) 218-225
128. Simpson E.R., and Dowsett M. Aromatase and its inhibitors: significance for breast cancer therapy. Recent Prog Horm Res 57 (2002) 317-338
129. Soberman J.E., and Weber K.T. Spironolactone in congestive heart failure. Curr Hypertens Rep 2 (2000) 451-456
130. Sonino N., and Boscaro M. Medical therapy for Cushing's disease. Endocrinol Metab Clin N Am 28 (1999) 211-222
131. Sonino N., Boscaro M., Ambroso G., Merola G., and Mantero F. Prolonged treatment of Cushing's disease with metyrapone and aminoglutethimide. IRCS Med Sci 14 (1986) 347-352
132. Stowasser M., Gordon R.D., Tunny T.J., Klemm S.A., Finn W.L., and Krek A.L. Familial hyperaldosteronism type II: five families with a new variety of primary aldosteronism. Clin Exp Pharmacol Physiol 19 (1992) 319-322
133. Sutherland D.J., Ruse J.L., and Ladidlaw J.C. Hypertension increased aldosterone secretion and low plasma rennin activity relieved by dexamethasone. Can Med Assoc J 95 (1966) 1109-1119
134. Swart A.C., Swart P., Roux S.P., van der Merwe K.J., Pretorius I.S., and Steyn A.J. Expression of human P450c17 as an export protein in Saccharomyces cerevisiae. Endocr Res 21 (1995) 289-295
135. Tamoaki B. Steroidogenesis and cell structure. Biochemical pursuit of sites of steroid biosynthesis. J Steroid Biochem 4 (1973) 89-118
136. Thai H.M., Van H.T., Gaballa M.A., Goldman S., and Raya T.E. Effects of AT1 receptor blockade after myocardial infarct on myocardial fibrosis, stiffness, and contractility. Am J Physiol 276 (1999) 873-880
137. Trachtenberg J. Ketoconazole therapy in advanced prostatic cancer. J Urol 132 (1984) 61-63
138. Ulmschneider S., Muller-Vieira U., Klein C.D., Antes I., Lengauer T., and Hartmann R.W. Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitors of aldosterone synthase. J Med Chem 48 (2005) 1563-1575
139. Ulmschneider S., Muller-Vieira U., Mitrenga M., Hartmann R.W., Oberwinkler-Marchais S., Klein C.D., et al. Synthesis and evaluation of imidazolylmethylenetetrahydronaphthalenes and imidazolylmethyleneindanes: potent inhibitors of aldosterone synthase. J Med Chem 48 (2005) 1796-1805
140. Van den Bossche H. Inhibitors of P450-dependent steroid biosynthesis: from research to medical treatment. J Steroid Biochem Mol Biol 43 (1992) 1003-1021
141. Vanden Bossche H., Ausma J., Bohets H., Vermuyten K., Willemsens G., Marichal P., et al. The novel azole R126638 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp., and Microsporum canis. Antimicrob Agents Chemother 48 (2004) 3272-3278
142. Vinson G.P. Glomerulosa function and aldosterone synthesis in the rat. Mol Cell Endocrinol 217 (2004) 59-65
143. Wada A., Ohnishi T., Nonaka Y., Okamoto M., and Yamano T. Synthesis of aldosterone by a reconstituted system of cytochrome P-45011 β from bovine adrenocortical mitochondria. J Biochem (Tokyo) 98 (1985) 245-256
144. Wagner M.J., Ge Y., Siciliano M., and Wells D.E. A hybrid cell mapping panel for regional localization of probes to human chromosome 8. Genomics 10 (1991) 114-125
145. Weber K.T., and Villarreal D. Aldosterone and antialdosterone therapy in congestive heart failure. Am J Cardiol 71 (1993) 3A-11A
146. Weber M.M., Will A., Adelmann B., and Engelhardt D. Effect of ketoconazole on human ovarian C17,20-desmolase and aromatase. J Steroid Biochem Mol Biol 38 (1991) 213-218
147. Weindel K., Lewicka S., and Vecsei P. Interference of C17-Spirnolactone with late steps of aldosterone biosynthesis. Structure-activity studies. Arzneimittelforschung 41 (1991) 1082-1091
148. White P.C. Steroid 11 β-hydroxylase deficiency and related disorders. Endocrinol Metab Clin N Am 30 (2001) 61-79
149. White P.C. Aldosterone synthase deficiency and related disorders. Mol Cell Biol 217 (2004) 81-87
150. White P.C., and Speiser P.W. Steroid 11 beta-hydroxylase deficiency and related disorders. Endocrinol Metab Clin N Am 23 (1994) 325-339
151. White P.C., Dupont J., New M.I., Leibermann E., Hochberg Z., and Rsler A. A mutation in CYP11B1 (Arg448His) associated with steroid 11β-hydroxylase deficiency in Jews of Moroccan origin. J Clin Invest 87 (1991) 1664-1667
152. Williams G., Kerle D.J., Doble A., Dunlop H., Smith C., Allen J., et al. Objective responses to ketoconazole therapy in patients with relapsed progressive prostate cancer. Br J Urol 58 (1986) 45-51
153. Williams P.A., Cosme J., Sridhar V., Johnson E.F., and McRee D.E. Mammalian microsomal cytochrome P450 monooxygenase: structural adaptations for membrane binding and functional diversity. Mol Cell 5 (2000) 121-131
154. Yanagibashi K., and Hall P.F. Role of electron transport in the regulation of the lyase activity of C21 side-chain cleavage P-450 from porcine adrenal and testicular microsomes. J Biol Chem 261 (1986) 8429-8433
155. Young M., and Funder J.W. Aldosterone and heart. Trends Endocrinol Metab 11 (2000) 224-226
156. Zachmann M., Tassinari D., and Prader A. Clinical and biochemical variability of congenital adrenal hyperplasia due to 11 beta-hydroxylase deficiency. A study of 25 patients. J Clin Endocrinol Metab 56 (1983) 222-229
157. Zachmann M., Vollmin J.A., Hamilton W., and Prader A. Steroid 17-20-desmolase deficiency: a new cause of male pseudohermaphroditism. Clin Endocricol 1 (1972) 369-385
158. Zhang L., Rodriguez H., Ohno S., and Miller W.L. Serine phosphorylation of human P450c17 increases 17,20-lyase activity: implications for adrenarche and the polycystic ovary syndrome. Proc Natl Acad Sci U S A 92 (1995) 10619-10623
159. Zhuang Y., Wachall B.G., and Hartmann R.W. Novel imidazolyl and triazolyl substituted biphenyl compounds: synthesis and evaluation as nonsteroidal inhibition of human 17α-hydroxylase-C17,20-lyase (P450 17). Bio M Ch 8 (2000) 1245-1252
160. Zuber M.X., John M.E., Okamura T., Simpson E.R., and Watermann M.R. Bovine adrenal cytochrome P45017: regulation of gene expression by ACTH and elucidation of primary sequence. J Biol Chem 261 (1986) 2475-2482